MoonLake Immunotherapeutics Newsroom

MoonLake Immunotherapeutics' Promising SLK Therapy Forecasts Strong Market Performance and Stock Potential

TipRanksNov 21 06:06 ET

UCB Gets FDA Approval for Bimzelx for Hidradenitis Suppurativa

Seeking AlphaNov 20 10:34 ET

MoonLake Immunotherapeutics Management to Meet With Oppenheimer

TipRanksNov 18 10:30 ET

Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $73

Moomoo NewsNov 14 10:31 ET · Ratings

MoonLake Immunotherapeutics' Promising Phase 3 Trials for PsA Treatment Drives Buy Rating

TipRanksNov 14 09:55 ET · Ratings

Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $104

Moomoo NewsNov 14 08:35 ET · Ratings

BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $71

Moomoo NewsNov 14 07:34 ET · Ratings

Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Advancements and Strong Market Potential

TipRanksNov 14 06:26 ET · Ratings

MoonLake Immunotherapeutics Announces First Patients Screened in IZAR Program

TipRanksNov 13 08:31 ET

Express News | MoonLake Immunotherapeutics: Topline Primary Endpoint Readout at Week 16 for Phase 3 Izar Program Expected in H1 2026

ReutersNov 13 08:03 ET

MoonLake Immunotherapeutics Starts Phase 3 IZAR Program of the Nanobody Sonelokimab in Patients With Active Psoriatic Arthritis

GlobeNewswireNov 13 08:00 ET

Express News | MoonLake Immunotherapeutics Starts Phase 3 Izar Program of the Nanobody® Sonelokimab in Patients With Active Psoriatic Arthritis

ReutersNov 13 08:00 ET

Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $62

Moomoo NewsNov 9 12:32 ET · Ratings

Barclays Maintains MoonLake Immunotherapeutics(MLTX.US) With Hold Rating, Maintains Target Price $55

Moomoo NewsNov 9 12:32 ET · Ratings

MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Dow JonesNov 8 14:29 ET · Ratings

A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $55 to $100

Moomoo NewsNov 8 08:00 ET · Ratings

Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Avidity Biosciences (RNA) and MoonLake Immunotherapeutics (MLTX)

TipRanksNov 8 06:10 ET · Ratings

Strategic Initiatives and Financial Stability Propel MoonLake Immunotherapeutics Towards Promising Market Position

TipRanksNov 8 05:16 ET

MoonLake Immunotherapeutics: Strategic Growth and Financial Stability Drive Buy Rating

TipRanksNov 7 09:55 ET · Ratings

MoonLake Immunotherapeutics Reports Q3 EPS (56c), Consensus (43c)

TipRanksNov 7 07:12 ET